ReviewFEBS letters2011
Translational application of epigenetic alterations: ovarian cancer as a model.
Review in FEBS letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Potential of histone deacetylase inhibitors for the therapy of ovarian cancer.Frontiers in oncology · 2022Review
- Klotho promoter methylation status and its prognostic value in ovarian cancer.Molecular and clinical oncology · 2021Article
- Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature.Cancers · 2021Article
- Review
- Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Epigenetics in ovarian cancer: premise, properties, and perspectives.Molecular cancer · 2018Review
- Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Cellular oncology (Dordrecht, Netherlands) · 2017Review
- Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.Journal of ovarian research · 2016Article
- Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.Journal of cellular and molecular medicine · 2016Review
- Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.Epigenetics · 2014Article
- Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Journal of cellular physiology · 2014Review
- Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.Epigenetics · 2013Article
- Ovarian cancer: in search of better marker systems based on DNA repair defects.International journal of molecular sciences · 2013Review
- Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.Current pharmaceutical design · 2013Review
- Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.British journal of pharmacology · 2012Review
- Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.Epigenetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer is a disease initiated and driven by the accumulation and interplay of genetic and epigenetic mutations of genes involved in the regulation of cell growth and signaling. Dysregulation of these genes and pathways in a cell leads to a growth advantage and clonal expansion. The epigenetic alterations involved in the initiation and progression of cancer are DNA methylation and histone modifications which interact to remodel chromatin, as well as RNA interference. These alterations can be used as candidate targets in molecular tests for risk, early detection, prognosis, prediction of response to therapy, and monitoring, as well as new therapeutic targets in cancer. In this review, we discuss the rationale, studies to date, and issues in the translational application of epigenetics using epithelial ovarian cancer as a specific example of all types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.